Trials soon ready
Clinical trials expected to report results within the next 12 months, ranked by potential. Each trial shows its estimated finish date — explained in plain language.
Showing the top 50 of 232 trials in this window.
-
Can a bone marrow trick make face transplants safer?
⭐️ CURE ⭐️ Recruiting nowBackground: The human face is critically important for breathing, eating, seeing, and speaking/ communicating, but its most important job may be to look like a human face. Devastating facial deformities often cause affected individuals to avoid human contact and disappear from so…
Results expected Aug 2026 (estimated)
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
One-Time injection aims to restore hearing in children born deaf
⭐️ CURE ⭐️ OngoingThis study intends to assess safety, tolerability, and efficacy of SENS-501 in children between the ages of 6-31 months with pre-lingual hearing loss due to a mutation in the Otoferlin gene.
Results expected Jul 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Sensorion • Aim: ⭐️ CURE ⭐️
Last updated Jul 10, 2026 00:00 UTC
-
Can a One-Two punch of CAR-T and lenalidomide beat tough leukemia?
⭐️ CURE ⭐️ Recruiting nowThis is a Phase I/II interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have been pretreated w…
Results expected Aug 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Vitebsk Regional Clinical Cancer Centre • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
⭐️ CURE ⭐️ OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: Arcellx, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Reward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
Could a stem cell transplant cure immune diseases?
⭐️ CURE ⭐️ Recruiting nowBackground: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective:…
Results expected Oct 2026 (estimated)
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:28 UTC
-
Could a Virus-Like particle vaccine outsmart polio?
⭐️ VACCINE ⭐️ OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 08, 2026 00:03 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Can specially trained immune cells flush out hidden HIV?
⭐️ CURE ⭐️ OngoingThis is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following…
Results expected Nov 2026 (estimated)
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
New hope for kids with leukemia: smarter chemo dosing could boost cures
⭐️ CURE ⭐️ OngoingAcute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous ly…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Dana-Farber Cancer Institute • Aim: ⭐️ CURE ⭐️
Last updated Jul 18, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lung cancer
⭐️ CURE ⭐️ Recruiting nowA study to evaluate the safety and feasibility of α-PD-L1/4-1BB DLL3 Chimeric Antigen Receptor (CAR)-T (BHP01) in patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate CAR-T cell dose. Next, In dose expansion phase, patients were assign two…
Results expected Dec 2026 (estimated)
Phase: PHASE1 • Sponsor: Sichuan University • Aim: ⭐️ CURE ⭐️
Last updated Jul 23, 2026 00:00 UTC
-
Hepatitis b cure breakthrough? new combo aims for 50%+ cure rate
⭐️ CURE ⭐️ Recruiting nowExploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overa…
Results expected Dec 2026 (estimated)
Phase: PHASE4 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: ⭐️ CURE ⭐️
Last updated Jul 09, 2026 00:00 UTC
-
Major RSV vaccine trial for seniors nears completion
⭐️ VACCINE ⭐️ OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Can donor immune cells be engineered to fight blood cancer?
⭐️ CURE ⭐️ Recruiting nowKCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell malignancies.
Results expected Feb 2027 (estimated)
Phase: PHASE1 • Sponsor: University College, London • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can a single eye injection restore sight in genetic blindness?
⭐️ CURE ⭐️ OngoingThis is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects…
Results expected Mar 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Ocugen • Aim: ⭐️ CURE ⭐️
Last updated Aug 02, 2026 00:00 UTC
Ocugen · OCGN NASDAQ Trade on eToro (ad)Reward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
⭐️ CURE ⭐️ Recruiting nowThis is a prospective, single-arm phase II clinical trial intended to investigate the efficacy of neoadjuvant CTLA-4 monoclonal antibody combined with PD-1 monoclonal antibody plus preoperative chemoradiotherapy for locally advanced esophageal cancer. A total of 44 patients with …
Results expected Apr 2027 (estimated)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: ⭐️ CURE ⭐️
Last updated Aug 09, 2026 00:00 UTC
-
Two-Drug combo aims to wipe out breast cancer before surgery in BRCA carriers
⭐️ CURE ⭐️ Recruiting nowThis study is an open-label, single-arm, multicenter clinical study. 64 patients with germline BRCA-mutated HER2-negative early breast cancer are planned to be enrolled and treated with fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of neoad…
Results expected Apr 2027 (estimated)
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: ⭐️ CURE ⭐️
Last updated Jul 23, 2026 00:00 UTC
-
Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
⭐️ CURE ⭐️ Recruiting nowThis phase I trial evaluates the best dose, possible benefits and/or side effects of fludarabine and cyclophosphamide with or without rituximab before CD19 chimeric antigen receptor T cells in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or h…
Results expected May 2027 (estimated)
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: ⭐️ CURE ⭐️
Last updated Jul 19, 2026 00:00 UTC
-
Can a gene therapy restore natural hearing after cochlear implants?
⭐️ CURE ⭐️ OngoingThis study will evaluate the safety, tolerability, and efficacy of EA0010 injection in patients with OTOF-related hearing loss who have already undergone cochlear implantation. Conventional gene therapy generally excludes cochlear implant recipients, based on the concern that the…
Results expected May 2027 (estimated)
Phase: NA • Sponsor: Shanghai EmayGene Technology Co., Ltd • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Lab-Grown skin could transform burn healing
⭐️ CURE ⭐️ Recruiting nowThis multicentre phase III clinical trial will target adults and adolescents of 12 years and older with severe burns to confirm the efficacy and functionality of denovoSkin™ in achieving wound closure and reducing scarring in patients with deep partial and full-thickness burns as…
Results expected Jun 2027 (estimated)
Phase: PHASE3 • Sponsor: CUTISS AG • Aim: ⭐️ CURE ⭐️
Last updated Aug 12, 2026 00:00 UTC
-
Can a single Gene-Editing injection stop a blinding corneal disease?
⭐️ CURE ⭐️ Not yet recruitingThe goal of this clinical trial is to evaluate the safety and efficacy of GEB-101 injection in subjects with TGFBI-related Corneal Dystrophy
Results expected Aug 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: GenEditBio Limited • Aim: ⭐️ CURE ⭐️
Last updated Aug 08, 2026 00:03 UTC
-
Can engineered immune cells tackle an incurable childhood brain tumor?
⭐️ CURE ⭐️ Recruiting nowThe CARMIGO Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults aged 2-16 years with Diffuse Midline Glioma (DMG). The study will evaluate the feasibility of gen…
Results expected Aug 2027 (estimated)
Phase: PHASE1 • Sponsor: University College, London • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can a One-Time gene infusion rewrite the fate of PKU?
⭐️ CURE ⭐️ Recruiting nowThis is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU). NGGT002 is a rAAV8 based vector carrying a functional copy of the human PAH gene. Par…
Results expected Aug 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd. • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease
⭐️ CURE ⭐️ Recruiting nowThis is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical or MUD allogeneic stem cell transplantation with CD…
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: New York Medical College • Aim: ⭐️ CURE ⭐️
Last updated Jul 29, 2026 00:00 UTC
-
Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
⭐️ CURE ⭐️ Recruiting nowEnrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFO…
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
New TB vaccine aims to prevent active lung disease in adults
⭐️ VACCINE ⭐️ OngoingThis study is a multicenter, double-blind, randomized, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of the GamTBvac recombinant subunit tuberculosis vaccine for the prevention of active non-HIV-associated pulmonary tuberculosis. The study is di…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 08, 2026 00:00 UTC
-
Aiming to cure esophageal cancer without the knife
⭐️ CURE ⭐️ OngoingThe present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with chemoradiation is an efficient and safe treatment o…
Results expected Jan 2027 (estimated)
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: ⭐️ CURE ⭐️
Last updated Aug 09, 2026 00:00 UTC
-
New mRNA vaccine aims to stop the stomach flu
⭐️ VACCINE ⭐️ OngoingThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Results expected Feb 2027 (estimated)
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:33 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New COVID-19 vaccine candidate tested alone or as a booster with mRNA shots
⭐️ VACCINE ⭐️ Recruiting nowThe main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in th…
Results expected Aug 2026 (estimated)
Phase: PHASE3 • Sponsor: Invivyd, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 14:00 UTC
InVivyd · IVVD NASDAQ Trade on eToro (ad) -
New chikungunya vaccine trial aims to protect millions
⭐️ VACCINE ⭐️ Recruiting nowA Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age
Results expected Sep 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: Bharat Biotech International Limited • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:24 UTC
-
Engineered immune cells take aim at Mesothelioma—Can they deliver?
⭐️ CURE ⭐️ OngoingThis study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an M…
Results expected Sep 2026 (estimated)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Jul 29, 2026 00:00 UTC
-
New marburg vaccine trial aims to stop deadly virus
⭐️ VACCINE ⭐️ OngoingA Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Results expected Oct 2026 (estimated)
Phase: PHASE2 • Sponsor: Albert B. Sabin Vaccine Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:14 UTC
-
New RSV vaccine candidate aims to shield older adults from severe lung infections
⭐️ VACCINE ⭐️ Recruiting nowThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 23, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighAiming at a cure or vaccine; success would still be major news.
Risk to the company Very lowA large company running many trials — it absorbs a failure here.
-
New needle treatment could replace surgery for curing Hormone-Driven high blood pressure
⭐️ CURE ⭐️ OngoingThe primary objective of WAVE is to test the hypothesis that thermal ablation (microwave or RFA) is non-inferior to surgery in the biochemical (and if so, in the clinical) cure of unilateral PA, according to the international consensus PASO criteria. Secondary objectives are to …
Results expected Nov 2026 (estimated)
Phase: NA • Sponsor: Queen Mary University of London • Aim: ⭐️ CURE ⭐️
Last updated Jul 19, 2026 00:00 UTC
-
Promising malaria vaccine candidates enter key trial in african children
⭐️ VACCINE ⭐️ OngoingThis is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months in Burkina Faso.
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:01 UTC
-
Pfizer gives lyme vaccine a fifth dose — will it boost protection?
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
HPV vaccine trial aims to protect women with HIV from cervical cancer
⭐️ VACCINE ⭐️ OngoingHuman papillomavirus (HPV) infection is the most common viral infection of the reproductive tract. Up to 80%of the sexually active females and men will be infected with HPV at some point in their lives and some may be repeatedly infected. The main burden of HPV-related disease is…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Serum Institute of India Pvt. Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 01, 2026 00:00 UTC
-
Heat, not surgery: new trial aims to cure thyroid cancer without a knife
⭐️ CURE ⭐️ Recruiting nowThis pilot, single-arm clinical study evaluates the feasibility, safety, and effectiveness of radiofrequency ablation (RFA) as a curative treatment for small, low-risk papillary thyroid cancer (PTC). The study will enroll 30 adult patients (≥18 years) with biopsy-confirmed PTC me…
Results expected Dec 2026 (estimated)
Phase: NA • Sponsor: University Health Network, Toronto • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:35 UTC
-
Personalized vaccine aims to train immune system against cancer
⭐️ VACCINE ⭐️ ENROLLING_BY_INVITATIONA Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Results expected Jan 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Jaime Leandro Foundation for Therapeutic Cancer Vaccines • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:11 UTC
-
Can two immunotherapy drugs eliminate early rectal cancer without surgery?
⭐️ CURE ⭐️ Not yet recruitingThis is a multi-site, prospective, non-randomized phase 2 study evaluating neoadjuvant botensilimab in combination with balstilimab for patients with microsatellite stable (MSS) / mismatch repair proficient (MMRp) early rectal cancer staged T1-T2 N0 by MRI and considered candidat…
Results expected Jan 2027 (estimated)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: ⭐️ CURE ⭐️
Last updated Aug 01, 2026 00:00 UTC
-
Triple threat: new vaccine aims to tackle three salmonella strains at once
⭐️ VACCINE ⭐️ OngoingThis is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV). The trial will proceed from adults, to children, to toddlers, and then to infants.
Results expected Jan 2027 (estimated)
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 01, 2026 00:00 UTC
-
New vaccine aims to shield sickle cell kids from deadly infections
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose…
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:08 UTC
Sanofi · SNY NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New mRNA shot targets bird flu: 4,000 volunteers needed
⭐️ VACCINE ⭐️ OngoingThe purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New malaria vaccine shows promise in african trial
⭐️ VACCINE ⭐️ Recruiting nowThis is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa. The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double d…
Results expected Feb 2027 (estimated)
Phase: PHASE2 • Sponsor: Sanaria Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:01 UTC
-
New sudan ebola vaccine moves to phase 2 trial in healthy adults
⭐️ VACCINE ⭐️ OngoingA Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Results expected Feb 2027 (estimated)
Phase: PHASE2 • Sponsor: Albert B. Sabin Vaccine Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:03 UTC
-
Can a vaccine stop stomach cancer from coming back?
⭐️ CURE ⭐️ OngoingThe purpose of this early proof-of-concept study to evaluate the safety and immunologic efficacy of AST-301 in gastric cancer patients with HER2 expression (including both HER2 low expression and overexpression) who have completed the standard adjuvant treatment (including those …
Results expected Feb 2027 (estimated)
Phase: PHASE2 • Sponsor: Aston Sci. Inc. • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
Reward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New meningitis vaccine trial aims to shield babies from deadly infection
⭐️ VACCINE ⭐️ Recruiting nowThe goal of this clinical trial is to evaluate the immunogenicity, safety, and immune persistence of the primary series of an investigational group ACYW135 meningococcal conjugate vaccine, as well as the immunogenicity and safety of a booster dose administered at 12 months of age…
Results expected Apr 2027 (estimated)
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 12, 2026 00:00 UTC
Sinovac Biotech Co., Ltd. · SVA NASDAQReward if it works Very highA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New dengue vaccine trial targets older adults and those with chronic illness
⭐️ VACCINE ⭐️ Recruiting nowDengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. Researchers have seen that dengue fever now also happens more often in elderly persons. The main aim of this study is to learn more about…
Results expected Apr 2027 (estimated)
Phase: PHASE3 • Sponsor: Takeda • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:24 UTC
Takeda · TAK NYSE Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Can a vaccine stop Antibiotic-Resistant gonorrhea?
⭐️ VACCINE ⭐️ Recruiting nowThe main goal of this trial is to evaluate the safety and immunogenicity of the candidate N. gonorrhoeae vaccine, LTB-NG6.
Results expected Apr 2027 (estimated)
Phase: PHASE1 • Sponsor: LimmaTech Biologics AG • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
⭐️ CURE ⭐️ OngoingThe main purpose of this study is to learn if a new combination of chemotherapy, in combination with low-dose radiation, will be safe for the patient, and at the same time provide the best opportunity to cure the bone marrow cancer. The combination of chemotherapy and radiation d…
Results expected May 2027 (estimated)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Jul 26, 2026 00:00 UTC
-
New mRNA vaccine against mpox enters key trial in africa
⭐️ VACCINE ⭐️ Recruiting nowThis is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.
Results expected Jun 2027 (estimated)
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 13, 2026 00:00 UTC
BioNTech SE · BNTX NASDAQ Trade on eToro (ad)Reward if it works HighAiming at a cure or vaccine; success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
One pill to wipe out worms? new trial tests Game-Changing treatment
⭐️ CURE ⭐️ Not yet recruitingThis study aims to assess the efficacy and safety of emodepside compared to mebendazole in adults and adolescents infected with T. trichiura, either as single infection or co-infections with hookworm and/or A. lumbricoides.
Results expected Jun 2027 (estimated)
Phase: PHASE3 • Sponsor: Swiss Tropical & Public Health Institute • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to a broker we have a commercial relationship with, and we may earn a commission if you open an account. This never affects which trials are listed or how they are ranked.